126 related articles for article (PubMed ID: 15620146)
21. [The expression of matrix metalloproteinase-9 and tumor necrosis factor-alpha in cholesteatoma].
Li N; Qin Z; Dong M
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2004 Jul; 18(7):424-6. PubMed ID: 15499988
[TBL] [Abstract][Full Text] [Related]
22. Matrix metalloproteinase-1 in cholesteatoma, middle ear granulations and deep meatal skin: a comparative analysis.
Banerjee AR; James R; Narula AA; Lee RJ
Clin Otolaryngol Allied Sci; 1998 Dec; 23(6):515-9. PubMed ID: 9884804
[TBL] [Abstract][Full Text] [Related]
23. [Expression of transforming growth factor-beta1 and c-fos and p27 in human middle ear cholesteatoma].
Jiang CW; Zhan HM; Wang WH; Zhang L; Jin SZ; Yang YB; Zhang ZJ
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2004 Apr; 39(4):211-5. PubMed ID: 15283280
[TBL] [Abstract][Full Text] [Related]
24. [The expression and significance of DDR2 and MMP-13in human middle ear cholesteatoma].
Xu LF; Sun WZ
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Jun; 30(12):938-941. PubMed ID: 29771058
[No Abstract] [Full Text] [Related]
25. Canal wall down tympanoplasty with canal reconstruction for middle-ear cholesteatoma: post-operative hearing, cholesteatoma recurrence, and status of re-aeration of reconstructed middle-ear cavity.
Ikeda M; Yoshida S; Ikui A; Shigihara S
J Laryngol Otol; 2003 Apr; 117(4):249-55. PubMed ID: 12816211
[TBL] [Abstract][Full Text] [Related]
26. Comparison of acquired cholesteatoma between pediatric and adult patients.
Dornelles Cde C; da Costa SS; Meurer L; Rosito LP; da Silva AR; Alves SL
Eur Arch Otorhinolaryngol; 2009 Oct; 266(10):1553-61. PubMed ID: 19322578
[TBL] [Abstract][Full Text] [Related]
27. [Expression of human papillomavirus DNA in cholesteatoma of the middle ear].
Bai Y; Yan L; Li S; Bai Q
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2000 Oct; 35(5):352-5. PubMed ID: 12768735
[TBL] [Abstract][Full Text] [Related]
28. Micronucleus frequency in acquired middle ear cholesteatoma.
Oztürk K; Yildirim MS; Acar H; Arikoğlu H; Arbağ H; Ozer B
Acta Otolaryngol; 2004 Oct; 124(8):924-8. PubMed ID: 15513528
[TBL] [Abstract][Full Text] [Related]
29. [Surgery of cholesteatoma of the ear canal].
Jahnke K; Lieberum B
Laryngorhinootologie; 1995 Jan; 74(1):46-9. PubMed ID: 7888023
[TBL] [Abstract][Full Text] [Related]
30. Increased presence of matrix metalloproteinases 2 and 9 in short- and long-term experimental herpes simplex virus encephalitis.
Martínez-Torres FJ; Wagner S; Haas J; Kehm R; Sellner J; Hacke W; Meyding-Lamadé U
Neurosci Lett; 2004 Sep; 368(3):274-8. PubMed ID: 15364410
[TBL] [Abstract][Full Text] [Related]
31. Telomerase activity and cell proliferation index in cholesteatoma.
Lee SH; Jang YH; Tae K; Park YW; Kang MJ; Kim KR; Park CW
Acta Otolaryngol; 2005 Jul; 125(7):707-12. PubMed ID: 16012031
[TBL] [Abstract][Full Text] [Related]
32. [The expression of Ras protein in human middle ear cholesteatoma].
Xu Y; Jin K; Dong W
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1999 Apr; 34(2):74-6. PubMed ID: 12764851
[TBL] [Abstract][Full Text] [Related]
33. Matrix metalloproteinase 2: an important genetic marker for cholesteatomas.
Morales DS; Penido Nde O; da Silva ID; Stávale JN; Guilherme A; Fukuda Y
Braz J Otorhinolaryngol; 2007; 73(1):51-7. PubMed ID: 17505599
[TBL] [Abstract][Full Text] [Related]
34. The formation of sinus in congenital stenosis of external auditory canal with cholesteatoma.
Zhao S; Han D; Wang D; Li J; Dai H; Yu Z
Acta Otolaryngol; 2008 Aug; 128(8):866-70. PubMed ID: 18607966
[TBL] [Abstract][Full Text] [Related]
35. Cholesteatoma gene expression of matrix metalloproteinases and their inhibitors by RT-PCR.
Rezende CE; Souto RP; Rapoport PB; Campos Ld; Generato MB
Braz J Otorhinolaryngol; 2012 Jun; 78(3):116-21. PubMed ID: 22714856
[TBL] [Abstract][Full Text] [Related]
36. Expressions of caspase-14 in human middle ear cholesteatoma.
Jung MH; Lee JH; Cho JG; Jung HH; Hwang SJ; Chae SW
Laryngoscope; 2008 Jun; 118(6):1047-50. PubMed ID: 18520823
[TBL] [Abstract][Full Text] [Related]
37. [The study of TNF-alpha destructive action to the bone in human middle cholesteatoma].
Xue Q; Jin K; Song H
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2001 Jan; 15(1):13-4. PubMed ID: 12541874
[TBL] [Abstract][Full Text] [Related]
38. Elevated level of tenascin and matrix metalloproteinase 9 correlates with the bone destruction capacity of cholesteatomas.
Juhász A; Sziklai I; Rákosy Z; Ecsedi S; Adány R; Balázs M
Otol Neurotol; 2009 Jun; 30(4):559-65. PubMed ID: 19395987
[TBL] [Abstract][Full Text] [Related]
39. Expression of matrix-degrading cysteine proteinase cathepsin K in cholesteatoma.
Hansen T; Unger RE; Gaumann A; Hundorf I; Maurer J; Kirkpatrick CJ; Kriegsmann J
Mod Pathol; 2001 Dec; 14(12):1226-31. PubMed ID: 11743044
[TBL] [Abstract][Full Text] [Related]
40. [Study of the relation between MMP2, MMP9 and nasopharyngeal carcinoma].
Zhang X; Guo Y; Ye Q; Yang Z; Dong Z
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 1999 Aug; 13(8):356-8. PubMed ID: 12541362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
